Introduction {#Sec1}
============

Exacerbations have a deleterious effect on the morbidity and mortality of patients with chronic obstructive pulmonary disease (COPD) \[[@CR1]\] by increasing hospitalization \[[@CR2]\], worsening lung function \[[@CR3]\] and health-related quality of life, and decreasing survival \[[@CR4]\]. As such, the prevention of exacerbations is an important goal of COPD therapy \[[@CR5]\], the importance of which is reflected in the current Global Initiative for Chronic Obstructive Lung Disease (GOLD) document on the management of COPD \[[@CR6]\].

The frequency of exacerbations increases in parallel with the severity of COPD \[[@CR7]\]. In the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE^®^) (ClinicalTrials.gov \#NCT00292552) observational study of patients with COPD, exacerbation rate was shown to increase with GOLD staging, such that 22% of patients with GOLD Stage II disease had two or more exacerbations during 1 year of follow-up, whereas 47% of patients with GOLD Stage IV disease had frequent exacerbations over the same period. Across all GOLD stages, the single best predictor of future episodes was prior exacerbations \[[@CR8]\]. Additionally, the results from the ECLIPSE study suggested that patients with COPD could be phenotyped according to their exacerbation risk. Those patients who experienced fewer than two exacerbations per year were classified as "infrequent exacerbators"; those experiencing two or more per year were classified as "frequent exacerbators" and considered to be different phenotypes \[[@CR8]\]. More recently, the GOLD 2013 guidelines revisited this classification of patients at risk for exacerbations and divided patients into low (≤1 exacerbations; no severe exacerbations) and high (≥2 or ≥1 severe exacerbation) risk categories \[[@CR6]\]. The critical difference between these classification systems is that, according to the ECLIPSE classification, one hospitalization (severe exacerbation) would suggest an infrequent exacerbator, whereas it would suggest a high-risk exacerbator according to the new GOLD classification \[[@CR6], [@CR8]\].

Few studies have investigated the effect of pharmacotherapy on COPD exacerbations in different subsets of exacerbator phenotype patients. The Prevention of Exacerbations with Tiotropium in Chronic Obstructive Pulmonary Disease (POET-COPD^®^) (ClinicalTrials.gov NCT00563381) study was a 1-year, randomized, double-blind, double-dummy, parallel-group trial that compared the effect of treatment with the long-acting anticholinergic tiotropium (18 μg via the HandiHaler^®^ device once daily) (SPIRIVA^®^, Boehringer Ingelheim Pharma and Co. KG, Ingelheim, Germany) with that of the long-acting β~2~-agonist (LABA) salmeterol (50 μg via a hydrofluoroalkane-pressurized metered-dose inhaler twice daily) on the incidence of moderate and severe exacerbations in 7376 patients with COPD and a history of exacerbations in the preceding year \[[@CR9]\]. The POET-COPD trial showed that, among the total patient population, tiotropium as compared with salmeterol (1) increased the time to the first exacerbation, (2) significantly increased the time to the first severe exacerbation, and (3) reduced the annual number of moderate or severe exacerbations \[[@CR9]\]. However, the impact of tiotropium and salmeterol specifically on patients at low or high risk of exacerbations has not been established.

The current study therefore investigated the effect of tiotropium and salmeterol on exacerbations in patients considered to be at a low or high risk for exacerbations (GOLD guidelines 2014 classification) and frequent/infrequent exacerbators (ECLIPSE study criteria) during a 1-year treatment period in a post hoc analysis of patients in the POET-COPD trial.

Methods {#Sec2}
=======

Study Design {#Sec3}
------------

POET-COPD was a 1-year, randomized, double-blind, double-dummy, parallel-group trial that analyzed the effect of tiotropium 18 μg once daily or salmeterol 50 μg twice daily on moderate to severe exacerbations in patients with COPD \[[@CR9]\]. The primary endpoint of the trial was time to first moderate or severe exacerbation. Secondary and safety endpoints included time to event, number of events, serious adverse events, and mortality. An exacerbation was defined as an increase in, or new onset of, at least two respiratory symptoms (cough, sputum, dyspnea, wheezing, chest tightness) with at least one symptom lasting for ≥3 days and leading the patient's attending physician to initiate treatment with systemic corticosteroids and/or antibiotics (moderate exacerbation) or request hospitalization (severe exacerbation) \[[@CR8], [@CR10]\]. Patients receiving fixed-dose combinations of LABAs and inhaled corticosteroids (ICS) switched to ICS monotherapy (on equal ICS dose) at the start of randomized treatment. All COPD medications, except for anticholinergics or LABAs, were permitted during the double-blind treatment phase. Inclusion criteria were age ≥40 years, smoking history ≥10 pack-years, diagnosis of COPD (post-bronchodilator forced expiratory volume in 1 s \[FEV~1~\] ≤70% predicted and FEV~1~/forced vital capacity ≤70%), and at least one exacerbation in the previous year requiring treatment with systemic steroids and/or antibiotics and/or hospitalization.

Statistical Analysis {#Sec4}
--------------------

The statistical tests were designed to test the hypothesis that tiotropium had a greater efficacy than salmeterol in preventing future exacerbations. Post hoc analyses were performed by the subgroups that were low/high risk at baseline and based on collected COPD characteristics, including hospitalization due to an exacerbation and medication use. A Cox proportional hazards regression model was used for time-to-exacerbation analyses. Hazard ratios (HR) and *p* values were based on stratified Cox regression with treatment as covariate. Poisson regression correcting for overdispersion and adjusting for treatment exposure and with terms for subgroup and treatment-by-subgroup interaction was used for number-of-event (exacerbations) analyses. The probability of a patient being considered at high risk for exacerbations during 1 year of treatment in the POET-COPD study was analyzed using a log-binomial model adjusting for treatment exposure and with terms for subgroup and treatment-by-subgroup interaction. A post hoc subgroup analysis was conducted to compare patients in each study group who were and were not receiving ICS at baseline. Statistical analyses were conducted using SAS^®^ version 9.2, SAS Institute Inc. 2009, Cary, North Carolina, USA.

This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.

Results {#Sec5}
=======

The baseline characteristics of patients stratified according to low/high exacerbation risk is summarized in Table [1](#Tab1){ref-type="table"}. Except for baseline lung function and baseline ICS use, patients in the low-risk (*n* = 2610) and high-risk (*n* = 4284) groups were balanced. Within the risk subgroups, there were no clinically relevant differences in the baseline characteristics of patients in the tiotropium and salmeterol groups (data not shown).Table 1Baseline characteristics of patients in each risk groupLow risk (*N* = 2610)High risk (*N* = 4284)Age, years63.4 (8.8)62.7 (9.1)Male, *n* (%)1946 (74.6)3220 (75.2)Smoking status, *n* (%) Ex-smoker1331 (51.0)2279 (53.2) Current smoker1278 (49.0)2005 (46.8)Time since diagnosis of COPD, years7.4 (6.5)8.3 (6.8)Spirometry FEV~1~, L1.47 (0.47)1.37 (0.45) FEV~1~, % predicted51.1 (13.0)48.0 (13.3)Respiratory medication taken at baseline, *n* (%) Anticholinergics1391 (53)2342 (55) ICS1308 (50)2411 (56) Other steroids43 (1.6)125 (3) LABA1355 (52)2239 (52) ICS + LABA (free or FDC)1097 (42)1929 (45)Data are mean (SD) unless otherwise specified*COPD* chronic obstructive pulmonary disease, *FDC* fixed-dose combination, *FEV* ~*1*~ forced expiratory volume in 1 s, *ICS* inhaled corticosteroids, *LABA* long-acting β~2~-agonist, *SD* standard deviation

Time to First COPD Exacerbation {#Sec6}
-------------------------------

Using the GOLD 2013 risk classification for exacerbations, tiotropium reduced the risk of a COPD exacerbation compared with salmeterol in patients classified as being at high risk or low risk for exacerbations (Fig. [1](#Fig1){ref-type="fig"}). A similar pattern was obtained when using the frequent/infrequent risk classification definition. Tiotropium also increased the time to first COPD exacerbation compared with salmeterol in patients classified as being at high risk for exacerbations (HR 0.84; 95% confidence interval \[CI\] 0.76--0.92; *p* = 0.0002) (Table [2](#Tab2){ref-type="table"}). In those patients classified as being at low risk for exacerbations, there was a non-significant increase in time to first COPD exacerbation for tiotropium compared with salmeterol (HR 0.89; 95% CI 0.77--1.02; *p* = 0.1046) (Table [2](#Tab2){ref-type="table"}).Fig. 1Cumulative risk of COPD exacerbations on treatment by patient exacerbation risk classification. *COPD* chronic obstructive pulmonary diseaseTable 2Time to first COPD exacerbation by patient exacerbation risk classificationPatient classificationTiotropiumSalmeterolTiotropium vs. salmeterol*n*Number of patients with events*n*Number of patients with eventsHR (95% CI)*p* valueLow risk132437512864020.89 (0.77--1.02)0.1046High risk213282421529930.84 (0.76--0.92)0.0002Infrequent exacerbator153143414844720.87 (0.77--0.99)0.0414Frequent exacerbator187874819018430.84 (0.76--0.93)0.0005*CI* confidence interval, *COPD* chronic obstructive pulmonary disease, *HR* hazard ratio

A similar pattern was obtained when using the frequent/infrequent risk classification definition. Tiotropium significantly increased the time to first COPD exacerbation compared with salmeterol in frequent exacerbators (HR 0.84; 95% CI 0.76--0.93; *p* = 0.0005) and infrequent exacerbators (HR 0.87; 95% CI 0.77--0.99; *p* = 0.0414) (Table [2](#Tab2){ref-type="table"}). Whether or not patients were on background ICS at baseline did not impact these results (Table [3](#Tab3){ref-type="table"}).Table 3Time to first COPD exacerbation by patient exacerbation risk history classification and ICS use at baselinePatient classificationTiotropiumSalmeterolTiotropium vs. salmeterol*n*Number of patients with events*n*Number of patients with eventsHR (95% CI)*p* valueLow risk (−ICS)6561516461710.85 (0.68--1.06)0.1415Low risk (+ICS)6682246402310.92 (0.76--1.10)0.3638High risk (−ICS)9243059493680.81 (0.69--0.94)0.0054High risk (+ICS)120851912035650.85 (0.76--0.96)0.0086*CI* confidence interval, *COPD* chronic obstructive pulmonary disease, *HR* hazard ratio, *ICS* inhaled corticosteroid

Number of COPD Exacerbations (Adjusted Annual Rates) {#Sec7}
----------------------------------------------------

Tiotropium significantly reduced the number of COPD exacerbations compared with salmeterol in patients classified as being at high risk for exacerbations (rate ratio \[RR\] 0.90; 95% CI 0.81--0.99; *p* = 0.0383; adjusted annual rates = 0.76 and 0.85 for tiotropium and salmeterol, respectively) (Fig. [2](#Fig2){ref-type="fig"}). When using the frequent/infrequent risk classification, there was a borderline significant reduction with tiotropium in the number of COPD exacerbations compared with salmeterol in patients classified as frequent exacerbators (RR 0.90; 95% CI 0.81--1.01; *p* = 0.0668; adjusted annual rates = 0.79 and 0.87 for tiotropium and salmeterol, respectively) and also in the number of COPD exacerbations compared with salmeterol in patients classified as infrequent exacerbators (RR 0.88; 95% CI 0.75--1.02; *p* = 0.0881; adjusted annual rates = 0.48 and 0.55 for tiotropium and salmeterol, respectively) (Fig. [2](#Fig2){ref-type="fig"}). In patients classified as being at low risk for exacerbations, there was a borderline significant reduction with tiotropium in the number of COPD exacerbations compared with salmeterol (RR 0.89; 95% CI 0.76--1.05; *p* = 0.1768; adjusted annual rates = 0.48 and 0.54 for tiotropium and salmeterol, respectively) (Fig. [2](#Fig2){ref-type="fig"}). The post hoc subgroup analysis comparing both high- and low-risk patients who were or were not receiving ICS at baseline showed similar trends towards tiotropium reducing the number of COPD exacerbations; however, in high-risk patients receiving ICS at baseline, this was a numerical difference only (Fig. [3](#Fig3){ref-type="fig"}).Fig. 2Number of COPD exacerbations after treatment by patient exacerbation risk classification. *CI* confidence interval, *COPD* chronic obstructive pulmonary disease, *RR* risk ratioFig. 3Number of COPD exacerbations after treatment by patient exacerbation risk classification and ICS use at baseline. *CI* confidence interval, *COPD* chronic obstructive pulmonary disease, *ICS* inhaled corticosteroid, *RR* risk ratio

Treatment-Induced Shifts in Patient Risk Classification {#Sec8}
-------------------------------------------------------

Comparing patients at low versus high risk for exacerbations before and after 1 year's treatment with either tiotropium or salmeterol showed that treatment resulted in a shift in the ratio (low/high exacerbation risk) from 0.62 to 4.98 and from 0.60 to 4.25 for treatment with tiotropium and salmeterol, respectively (Table [4](#Tab4){ref-type="table"}). When using the infrequent versus frequent for exacerbations definition, shifts in the ratio (infrequent/frequent exacerbations) were larger (from 0.82 to 6.44 and from 0.78 to 5.80 for treatment with tiotropium and salmeterol, respectively) (Table [4](#Tab4){ref-type="table"}). The risk of remaining in the high-risk subgroup for exacerbations after 1 year of treatment was statistically lower in the tiotropium group than in the salmeterol group (RR 0.89; 95% CI 0.80--1.00; *p* = 0.0478) (Table [5](#Tab5){ref-type="table"}). The risk of patients who were in the low-risk subgroup for exacerbations in the previous year being considered at high risk for exacerbations after 1 year's treatment was statistically lower in the tiotropium group compared with salmeterol (RR 0.87; 95% CI 0.71--1.07; *p* = 0.1968) (Table [5](#Tab5){ref-type="table"}).Table 4Comparison of patient classifications before and during treatmentRisk classificationECLIPSE^®^ exacerbation frequency definition (frequent/infrequent exacerbator)\
*N* = 6794GOLD 2013/4 risk definition (high risk/low risk)\
*N* = 6894TiotropiumSalmeterolTiotropiumSalmeterolBefore 1 year of treatment (low/infrequent), *n* ^a^ (%)1531 (22.5)1484 (21.8)1324 (19.2)1286 (18.7)During 1 year of treatment (low/infrequent), *n* ^a^ (%)2951 (43.4)2887 (42.5)3087 (44.8)2970 (43.1)Before 1 year of treatment (high/frequent), *n* ^a^ (%)1878 (27.6)1901 (28.0)2132 (30.9)2152 (31.2)During 1 year of treatment (high/frequent), *n* ^a^ (%)458 (6.7)498 (7.3)620 (9.0)699 (10.1)Ratio infrequent (low risk)/frequent (high risk) during 1 year before study0.820.780.620.60Ratio infrequent (low risk)/frequent (high risk) on treatment6.445.804.984.25Ratio difference (on treatment---before study)5.625.024.363.65*ECLIPSE* ^*®*^ Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints, *GOLD* Global Initiative for Chronic Obstructive Lung Disease^a^Total patient populationTable 5Probability of shifts to high-risk/frequent exacerbator group with tiotropium and salmeterol treatmentPrior to treatmentOn-treatment Exacerbation frequency, *n* (%)Probability of shifting to high-risk/frequent exacerbator category (tiotropium versus salmeterol)Low risk/infrequentHigh risk/frequentRR (95% CI)*p* valueTiotropiumSalmeterolTiotropiumSalmeterolLow risk1172 (88.5)1117 (86.9)152 (11.5)169 (13.1)0.87 (0.71--1.07)0.1968High risk1692 (79.4)1654 (76.9)440 (20.6)498 (23.1)0.89 (0.80--1.00)0.0478Infrequent exacerbator1382 (90.3)1326 (89.4)149 (9.7)158 (10.6)0.91 (0.74--1.13)0.4065Frequent exacerbator1569 (83.5)1561 (82.1)309 (16.5)340 (17.9)0.92 (0.80--1.06)0.2436*CI* confidence interval, *RR* risk ratio

Discussion {#Sec9}
==========

This post hoc analysis of the POET-COPD trial, which investigated the effect of tiotropium and salmeterol on exacerbations in patients considered to be at a low or high risk for exacerbations during the 1-year treatment period, had two main findings. First, it confirmed the higher efficacy of tiotropium compared with salmeterol in prolonging the time to first COPD exacerbation and reducing the number of COPD exacerbations in patients considered to be at low risk, as well as in those considered to be at high risk, for exacerbations. Second, our results show that background ICS usage at baseline, or lack thereof, had no impact on tiotropium's efficacy (versus salmeterol) with regard to reducing the exacerbation frequency among patients with COPD, regardless of their risk classification. Although the original trial was not set up to test this, tiotropium, and to a lesser extent salmeterol, appears to shift patients in the high-risk classification group to the low-risk group, suggesting a stabilizing effect on the disease.

The initial observation from the current analysis, that tiotropium had a greater efficacy than salmeterol in prolonging the time to first COPD exacerbation, confirms the primary results among the total patient population for the POET-COPD trial. Additionally, although not formally tested, our results suggest that the impact of tiotropium versus salmeterol on exacerbations was greater among those patients classified as being at high risk for exacerbations, regardless of whether the ECLIPSE \[[@CR8]\] or recent GOLD \[[@CR6]\] definitions are applied. In those patients classified as being at low risk for exacerbations, the results were borderline significant in favor of tiotropium, whereas in the high-risk group, this difference was statistically significant in favor of tiotropium. This might be explained by a lower number of exacerbations in the low-risk group.

It is noteworthy that the comparable effect observed from treatment with tiotropium versus salmeterol on COPD exacerbations does not appear to be influenced by the concomitant use of background ICS, although the risk ratio is more favorable for tiotropium when compared with salmeterol in both low- and high-risk exacerbator groups that were not using ICS.

Not only did our results show that treatment with tiotropium or salmeterol resulted in a higher proportion of patients shifting from the high-risk (frequent) to the low-risk (infrequent) exacerbator group, but also that treatment prevented patients at low risk of exacerbations from transitioning into the high-risk group. Many studies have shown that intervention with pharmacotherapy confers benefit to patients with COPD by reducing exacerbations or prolonging the time to first exacerbation \[[@CR11]--[@CR14]\]; however, few have successfully demonstrated that pharmacotherapy can positively influence the future risk of patients experiencing exacerbations \[[@CR15]\]. As observed in other interventional trials both in COPD and asthma \[[@CR13], [@CR16]\], the overall shift in the exacerbation frequency prior to enrollment versus randomized treatment is remarkable and somehow surprising, particularly in comparison to the relative stability of the phenotype in an observational setting \[[@CR17]\]. While insufficient background COPD treatment prior to inclusion may at least partially explain this strong shift, other factors may also be relevant such as the definition and documentation of exacerbations \[[@CR18]\] (e.g., post hoc for history of exacerbations vs. prospectively on trials) as well as recall or reporting of exacerbations \[[@CR19]\].

We speculate that by intervening early in the disease process, it may therefore be possible to minimize deleterious effects associated with increased frequency and severity of exacerbations in patients with COPD.

A limitation of the current study is that the POET-COPD trial was not designed to evaluate the effect of tiotropium specifically in different exacerbator phenotypes, nor was it designed to evaluate the effect of tiotropium on mitigating future risk for exacerbations. However, the detailed information regarding exacerbation history before enrollment and subsequently recorded over the course of the study, the large number of patients that participated, and the careful attention to study outcomes provides confidence in the results.

Conclusion {#Sec10}
==========

The results from the current study provide further evidence for intervention with tiotropium as maintenance therapy in COPD patients both at low or high risk for exacerbations.
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